# Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD)

> **NCT07643025** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Dennis Kim** · enrollment: 53 (estimated)

## Conditions studied

- cGVHD

## Interventions

- **DRUG:** Belumosudil
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT07643025
- **Lead sponsor:** Dennis Kim
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11
- **Primary completion:** 2029-11
- **Final completion:** 2030-11
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2026-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07643025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07643025, "Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07643025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*